Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people

with raised triglycerides 1 Recommendations 1.1 Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/ litre or above) and are taking statins, but only if they have: • established cardiovascular disease (secondary prevention), defined as a history of any of the following: － acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation) － coronary or other arterial revascularisation procedures － coronary heart disease － ischaemic stroke － peripheral arterial disease, and • low-density lipoprotein cholesterol (LDL-C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre. 1.2 This recommendation is not intended to affect treatment with icosapent ethyl that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Why the committee made these recommendations There are currently no treatment options to reduce the risk of cardiovascular events in people taking statins who have controlled levels of
